ProQR Therapeutics Valuation
| PRQR Stock | USD 3.67 0.23 6.69% |
At this time, the company appears to be undervalued. ProQR Therapeutics holds a recent Real Value of $3.9 per share. The prevailing price of the company is $3.67. Our model determines the value of ProQR Therapeutics from analyzing the company fundamentals such as Shares Outstanding of 105.91 M, operating margin of (2.19) %, and Return On Equity of -0.67 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting ProQR Therapeutics' valuation include:
Price Book 13.9639 | Enterprise Value 313.1 M | Enterprise Value Ebitda (2.10) | Price Sales 21.1399 | Enterprise Value Revenue 15.4815 |
Undervalued
Today
Please note that ProQR Therapeutics' price fluctuation is extremely dangerous at this time. Calculation of the real value of ProQR Therapeutics is based on 3 months time horizon. Increasing ProQR Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the ProQR stock is determined by what a typical buyer is willing to pay for full or partial control of ProQR Therapeutics BV. Since ProQR Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ProQR Stock. However, ProQR Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.67 | Real 3.9 | Target 3.93 | Hype 3.3 |
The intrinsic value of ProQR Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence ProQR Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of ProQR Therapeutics BV helps investors to forecast how ProQR stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ProQR Therapeutics more accurately as focusing exclusively on ProQR Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use ProQR Therapeutics' intrinsic value based on its ongoing forecasts of ProQR Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against ProQR Therapeutics' closest peers.
ProQR Therapeutics Cash |
|
ProQR Valuation Trend
ProQR Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of ProQR Therapeutics' financial worth over time. Using both ProQR Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
ProQR Therapeutics Total Value Analysis
ProQR Therapeutics BV is at this time projected to have valuation of 313.14 M with market capitalization of 388.68 M, debt of 19.73 M, and cash on hands of 156.4 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the ProQR Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
313.14 M | 388.68 M | 19.73 M | 156.4 M |
ProQR Therapeutics Investor Information
About 14.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.31. ProQR Therapeutics had not issued any dividends in recent years. Based on the key indicators related to ProQR Therapeutics' liquidity, profitability, solvency, and operating efficiency, ProQR Therapeutics BV is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.ProQR Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. ProQR Therapeutics has an asset utilization ratio of 4.72 percent. This connotes that the Company is making $0.0472 for each dollar of assets. An increasing asset utilization means that ProQR Therapeutics BV is more efficient with each dollar of assets it utilizes for everyday operations.ProQR Therapeutics Ownership Allocation
ProQR Therapeutics owns a total of 105.91 Million outstanding shares. ProQR Therapeutics holds 14.49 pct. of its outstanding shares held by insiders and 24.9 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.ProQR Therapeutics Profitability Analysis
The company reported the previous year's revenue of 6.51 M. Net Loss for the year was (27.54 M) with profit before overhead, payroll, taxes, and interest of 4.8 M.About ProQR Therapeutics Valuation
The stock valuation mechanism determines ProQR Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of ProQR Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of ProQR Therapeutics. We calculate exposure to ProQR Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of ProQR Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 6.4 M | 6.7 M | |
| Pretax Profit Margin | (4.27) | (4.48) | |
| Operating Profit Margin | (4.89) | (5.14) | |
| Net Loss | (4.32) | (4.53) | |
| Gross Profit Margin | 0.98 | 1.03 |
ProQR Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as ProQR Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 81 M |
ProQR Therapeutics Current Valuation Indicators
ProQR Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final ProQR Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as ProQR Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use ProQR Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes ProQR Therapeutics' worth.Additional Tools for ProQR Stock Analysis
When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.